Copyright
©The Author(s) 2022.
World J Gastroenterol. Jan 7, 2022; 28(1): 96-107
Published online Jan 7, 2022. doi: 10.3748/wjg.v28.i1.96
Published online Jan 7, 2022. doi: 10.3748/wjg.v28.i1.96
Table 1 Regional prevalence of hepatitis C virus genotypes
| Regions | G1 (%) | G2 (%) | G3 (%) | G4 (%) | G5 (%) | G6 (%) | Mixed |
| Africa | 26.3 | 23.7 | 6.3 | 28.1 | 12.2 | - | 3.4 |
| North Africa/Middle East | 27.3 | 0.8 | 6.3 | 65.3 | 0.3 | - | - |
| North America | 66.3 | 13.1 | 15.7 | 4.3 | - | 0.6 | - |
| Caribbean | 83 | 7.2 | 2.1 | 0.6 | - | 0.1 | 7.0 |
| Central Latin America | 74.6 | 21.6 | 3.3 | 0.1 | 0.1 | - | 0.3 |
| Central Asia | 70.4 | 8.6 | 19.6 | - | - | - | 1.4 |
| South Asia | 15.5 | 1.9 | 66.7 | 3.7 | 0.1 | 0.5 | 11.6 |
| Europe | 64.4 | 5.5 | 25.5 | 3.7 | 0.1 | 0.1 | 0.7 |
| Australasia | 55.0 | 6.5 | 36.0 | 1.2 | - | 1.3 | - |
Table 2 Current therapies for treatment of chronic hepatitis C
| Year approved | FDA approved therapy | Genotype | Trade name |
| 2011 | PegIFN/RBV + Boceprevir | Genotype-1 | Victrelis® |
| 2011 | Telaprevir + PegIFNα/RBV | Genotype-1 | Incivek® |
| 2013 | Sofosbuvir + RBV or Sofosbuvir + PegIFNα/RBV | Genotype-1, 2, 3 and 4 | Sovaldi® |
| 2014 | Ledipasvir + Sofosbuvirwith or without RBV | Genotype-1, 4, 5 and 6 | Harvoni® |
| 2015 | Daclatasvir + Sofosbuvir with or without RBV | Genotype-1, and 3 | Daklinza™ + Sovaldi® |
| 2016 | Grazoprevir + Elbasvir + RBV | Genotype-1, and 4 | Zepatier™ |
| 2016 | Velpatasvir + Sofosbuvir | Genotype 1 to 6 | Epclusa® |
| 2017 | Glecaprevir + Pibrentasvir | Genotype 1 to 6 | Mavyret™ |
| 2017 | Sofosbuvir + Velpatasvir + Voxilaprevir | Genotype 1 to 6 | Vosevi® |
- Citation: Luna-Cuadros MA, Chen HW, Hanif H, Ali MJ, Khan MM, Lau DTY. Risk of hepatocellular carcinoma after hepatitis C virus cure. World J Gastroenterol 2022; 28(1): 96-107
- URL: https://www.wjgnet.com/1007-9327/full/v28/i1/96.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i1.96